NCT06551896View on ClinicalTrials.gov

Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 15, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

December 31, 2026

Conditions
Urothelial CarcinomaBreast NeoplasmsLung CancerGastric CancerSoft Tissue SarcomaOther Carcinoma
Interventions
DRUG

Pemigatinib

Pemigatinib and immune checkpoint inhibitors

All Listed Sponsors
lead

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER

NCT06551896 - Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor | Biotech Hunter | Biotech Hunter